Abstract：Objective: To study the clinical effect of duloxetine combined with pregabalin in the treatment of fibromyalgia syndrome on improving pain symptoms and psychological disorders of patients. Methods: In this prospective study, 120 patients with fibromyalgia syndrome who were treated in our hospital from June 2020 to June 2022 were selected as research subjects. All patients were treated with pregabalin, and patients in the observation group were treated with duloxetine on this basis, and both groups were treated for 6 months. Differences in treatment outcomes, pain, negative emotions, sleep, fatigue, and safety were compared between the two groups. Results: The comparison of VAS scores between the control group and the observation group before treatment was statistically insignificant (P>0.05), and significantly decreased after treatment in both groups, and VAS scores in the observation group were significantly decreased at each time point after treatment compared with the control group (P<0.05). Statistically, there was no significant difference in HAMA and HAMD scores between the control group and the observation group before treatment (P>0.05). After treatment, the HAMA and HAMD scores in the observation group were significantly lower than those in the control group. The total effective rate of observation group (95.00%) was significantly higher than that of control group (83.33%). The comparison of PSQI score and FSS score between the control group and the observation group before treatment was statistically insignificant (P>0.05), and the two groups were significantly reduced after treatment. The change degree of PSQI score and FSS score in the observation group was significantly higher than that in the control group. There was no significant difference in the incidence of adverse reactions between the two groups during treatment(P>0.05). Conclusion: When duloxetine combined with pregabalin was used to treat fibromyalgia syndrome, the pain, sleep quality and psychological status of the patients were significantly improved, and the therapeutic effect was good.
[1] 李阳,贾园,肖语雅,等.纤维肌痛综合征的就诊现状及误诊漏诊分析[J].中华风湿病学杂志,2022,26(9):596-602. [2] 赵纬,何建群,郑艳峰.肥胖对纤维肌痛综合征妇女症状及生活质量的影响[J].中国妇幼保健,2021,36(10):2239-2241. [3] 李延婷,姜泉,焦娟,等.纤维肌痛综合征肝气郁结证患者躯体症状与心理症状的相关性[J].中医杂志,2020,61(18):1623-1627. [4] 邱勇,裴作为,汪芳.纤维肌痛综合征运动疗法的最佳选择尚待明确[J].中国全科医学,2021,24(23):2898-2901,2906. [5] 复杂性区域疼痛综合征和纤维肌痛病人的身体变化及感官敏感度[J].中国疼痛医学杂志,2021,27(3):166-169. [6] 纤维肌痛临床诊疗中国专家共识编写组.纤维肌痛临床诊疗中国专家共识[J].中国疼痛医学杂志,2021,27(10):721-727. [7] 徐愿,罗静,韩曼,等.中医药治疗风湿免疫领域临床优势病种的探讨[J].中国实验方剂学杂志,2022,28(9):198-204. [8] Goebel,Andreas,Andersson,et al.Research recommendations following the dscovery of pain sensitizing IgG autoantibodies in fibromyalgia syndrome[J].2022,23(6):1084-1094. [9] Burhan,Gucmen,Burhan fatih,et al.The relationship between cervical proprioception and balance in patients with fibromyalgia syndrome[J].2022,42(2):311-318. [10] Marina,Detommaso,Eleonora,et al.The puzzle of fibromyalgia between central sensitization syndrome and small fiber neuropathy:a narrative review on neurophysiological and morphological evidence[J].2022,43(3):1667-1684. [11] 戴丽华.普瑞巴林联合度洛西汀治疗纤维肌痛:一项随机对照试验[J].中国疼痛医学杂志,2017,23(3):165-167.
2023, Vol. 29 
冀公网安备13080202000677号